Ketamine for Treatment-Resistant Depression (eBook)

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation 'ketamine-like' fast-acting antidepressants.

Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose.

This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research. 

Sanjay J. Mathew, M.D. is the Johnson Family Chair for Research in Psychiatry, Professor with Tenure in the Menninger Department of Psychiatry and Behavioral Sciences, and director of the Mood and Anxiety Disorders Research Program at Baylor College of Medicine. He is a staff psychiatrist at the Michael E. Debakey VA Medical Center in Houston. He completed his psychiatric residency at Columbia University and the New York State Psychiatric Institute, where he also completed a research fellowship in affective and anxiety disorders. Dr Mathew began his faculty career at the Mount Sinai School of Medicine, where he co-founded and directed the Mood and Anxiety Disorders Program. He has led his current program since 2010.

Dr Mathew has published approximately 100 articles in leading scientific journals, and serves on the editorial board of several journals. He is an elected member of the American College of Neuropsychopharmacology and has been selected in Best Doctors every year since 2011.